LogicBio Therapeutics (NASDAQ: LOGC) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare LogicBio Therapeutics to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, institutional ownership, dividends and valuation.
This table compares LogicBio Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LogicBio Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
This is a summary of current ratings for LogicBio Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LogicBio Therapeutics Competitors||837||2781||6069||261||2.58|
LogicBio Therapeutics presently has a consensus target price of $23.33, suggesting a potential upside of 92.04%. As a group, “Biological products, except diagnostic” companies have a potential upside of 39.60%. Given LogicBio Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe LogicBio Therapeutics is more favorable than its competitors.
Earnings and Valuation
This table compares LogicBio Therapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|LogicBio Therapeutics||N/A||-$17.62 million||-4.00|
|LogicBio Therapeutics Competitors||$897.64 million||$190.37 million||-1.26|
LogicBio Therapeutics’ competitors have higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
56.5% of LogicBio Therapeutics shares are held by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 43.5% of LogicBio Therapeutics shares are held by company insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
LogicBio Therapeutics beats its competitors on 8 of the 12 factors compared.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.